Drug distributor McKesson and private equity firm Clayton Dubilier & Rice agreed Tuesday to take infusion therapy provider Option Care Health private in a $5.8 billion transaction. The deal pairs a Fortune 15 distribution giant with a top-tier buyout shop to control the largest independent home and alternate-site infusion operator in the United States.
Option Care manages over 100 infusion sites and handles complex biologic therapies in patients' homes and outpatient centers. McKesson already distributes specialty pharmaceuticals to Option Care and other infusion networks. CD&R brings operational playbook experience from healthcare services rollups and prior pharmaceutical infrastructure bets. The buyer consortium did not disclose the equity split, deal structure, or expected close date, though these transactions typically require Hart-Scott-Rodino clearance and state insurance approvals spanning four to six months.
The move matters because site-of-care economics are shifting faster than reimbursement maps can keep up. Payers increasingly steer high-cost biologic infusions—oncology, immunology, rare disease—away from hospital outpatient departments toward lower-cost home settings. Option Care sits at that fulcrum. Taking the company private removes quarterly earnings pressure and lets the operators re-engineer care protocols, negotiate directly with health plans, and potentially tuck in smaller regional infusion chains without public-market scrutiny. McKesson secures a captive downstream customer and gains data on which therapies move to alternate sites, intelligence worth more than the distribution margin alone. CD&R gets a platform in a structurally advantaged segment with mid-teens percentage annual growth in home infusion volumes, driven by an aging population and越来越复杂biologic pipelines from the top 20 biopharma companies.
Operators and allocators should watch three developments over the next six months. First, whether McKesson and CD&R attempt add-on acquisitions of regional infusion providers—there are roughly 30 sizeable independents left—signaling a broader consolidation thesis. Second, any contractual shifts between Option Care and the top five commercial payers, particularly UnitedHealth and Elevance, which together control 70 million covered lives and have been piloting home infusion mandates in select geographies. Third, how quickly McKesson integrates Option Care's patient data into its oncology and biopharma services units, potentially creating a closed-loop model that competes with specialty pharmacy benefit managers.
McKesson's stock closed flat on the news. The market already priced in the company's push into higher-margin specialty and oncology services. What the market has not yet priced: the optionality of owning the infusion site when the next wave of GLP-1 combination therapies and gene therapies require supervised administration outside the hospital.
The takeaway
McKesson and CD&R buy the site-of-care shift, not just the infusion provider.
Editorial & Disclosure Notice: This article was written with artificial intelligence from public sources and is published without individual human review. Artificial intelligence and other digital tools are also used for research, analysis, editing, formatting, and production. Errors, omissions, outdated information, or inaccuracies may occur. References to companies, brands, products, services, organizations, or individuals are for informational and editorial purposes and do not imply endorsement, sponsorship, affiliation, partnership, or approval unless expressly stated. All trademarks and other intellectual property remain the property of their respective owners. Opinions, analysis, estimates, and commentary are informational only and should not be construed as financial, investment, legal, tax, medical, procurement, or other professional advice. Information may be corrected, clarified, or updated after publication. Corrections or removal requests: jenny@pops4.com.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.